Search - tctmd.com

Displaying 481 - 500 of 1012

Sort: Relevancy | Date

Presentation TVT 2017

Fully Absorbable Patch-Based Large Hole Vascular Closure Device - EU Multi-center Clinical Experience

Presenter: Juan F. Granada, Martin B. Leon, Gregg W. Stone, Michael Laule, MD

June 14, 2017

Presentation SWVS 2017

Heart Valve Dysfunction With ESRD: Options and Expectations

Presenter: Michael J. Reardon

May 06, 2017

Presentation Fellows 2017

Update on Mitral Valve Disease and Transcatheter Therapies for Non-Aortic Valves

Presenter: Susheel Kodali, Michael J. Rinaldi

April 09, 2017

Presentation ECHO 2017

Cardiac Transplant: The Role of Echo

Presenter: Michael H. Picard

April 01, 2017

Presentation ECHO 2017

Mechanical Complications of MI: Case Ilustrations

Presenter: Michael H. Picard

April 01, 2017

Presentation ECHO 2017

Echocardiography in the Management of Patients With Left Ventricular Assist Devices

Presenter: Michael H. Picard

March 31, 2017

Presentation ECHO 2017

Guidelines: Assessment of ASD and PFO and Evaluation of a Cardiac Source of Embolism

Presenter: Michael H. Picard

March 31, 2017

Presentation SIF 2017

Cardiac CTA for LAA Occlusion Planning and Follow Up

Presenter: Michael J. Rinaldi

March 08, 2017

Presentation SIF 2017

Mechanical Circulatory Support in the Setting of STEMI PCI and Cardiogenic Shock

Presenter: Michael J Lim

March 08, 2017

Presentation ISET 2017

Understanding the Epidemic of CLI and Its Implications

Presenter: Michael R. Jaff

February 06, 2017

Presentation CHIP Florida 2017

Case: 50 year old white male prior history of DES stent to RCA

Presenter: Michael Yen

January 20, 2017

An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention

Presentation AHA 2016

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

Presenter: Michael Gibson

November 15, 2016

AEGIS-I Trial: The Safety and Tolerability of CSL112

Presentation AHA 2016

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Presenter: Michael Gibson

November 15, 2016

Presentation TCT 2016

Highlights (and my Interpretations) From: RESPECT Final Long-term Outcomes

Presenter: Jeffrey J. Popma, E. Murat Tuzcu, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

Available Devices/Techniques for Closure of PFO

Presenter: John D. Carroll, Christian Spies, Michael J. Mullen

November 01, 2016

Presentation TCT 2016

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Presenter: Freek W.A. Verheugt, Pascal Vranckx, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

Presenter: David P. Faxon, C. Michael Gibson, Deepak L. Bhatt

November 01, 2016

Presentation TCT 2016

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Presenter: David P. Faxon, C. Michael Gibson, Roxana Mehran

November 01, 2016

Presentation TCT 2016

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

Presenter: David P. Faxon, C. Michael Gibson

November 01, 2016

Presentation TCT 2016

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Presenter: David P. Faxon, C. Michael Gibson, Dominick J. Angiolillo

November 01, 2016

Advertisement

Fully Absorbable Patch-Based Large Hole Vascular Closure Device - EU Multi-center Clinical Experience

Heart Valve Dysfunction With ESRD: Options and Expectations

Update on Mitral Valve Disease and Transcatheter Therapies for Non-Aortic Valves

Cardiac Transplant: The Role of Echo

Mechanical Complications of MI: Case Ilustrations

Echocardiography in the Management of Patients With Left Ventricular Assist Devices

Guidelines: Assessment of ASD and PFO and Evaluation of a Cardiac Source of Embolism

Cardiac CTA for LAA Occlusion Planning and Follow Up

Mechanical Circulatory Support in the Setting of STEMI PCI and Cardiogenic Shock

Understanding the Epidemic of CLI and Its Implications

Case: 50 year old white male prior history of DES stent to RCA

PIONEER Trial: An OPen-label, Randomized, Controlled, Multicenter Study ExplorIng TwO TreatmeNt StratEgiEs of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy

The Safety and Tolerability of CSL112, a Reconstituted, Infusible, Plasma-Derived Human ApoA-I, After Acute Myocardial Infarction: The ApoA-I Event reducingG in Ischemic Syndromes I Trial (AEGIS-I)

Highlights (and my Interpretations) From: RESPECT Final Long-term Outcomes

Available Devices/Techniques for Closure of PFO

The PIONEER Trial: Rivaroxaban in Patients With ACS and Atrial Fibrillation: Design, Rationale, and Status

Acute Anticoagulation Management and Bleeding Avoidance Strategies in the Chronic AF Patient Who Requires PCI

When and Which Antiplatelet Agent Should be Dropped When Using Oral Anticoagulant Therapy?

Dosing Considerations of Oral Anticoagulant Therapy in the ACS and PCI Patient: Optimizing Efficacy While Minimizing Bleeding

General Overview and Highlights of the North American Consensus Document on Anticoagulation in the Atrial Fibrillation Patient With ACS or PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content